Beam Therapeutics has appointed Eric Foster as chief commercial officer.
Mr Foster will lead Beam’s commercial organisation and strategy as the company advances multiple product candidates across its haematology and genetic disease franchises toward potential launches.
Mr Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx.
Prior to Ardelyx, Mr Foster served as senior vice president and US general manager at Amgen following the acquisition of Horizon Therapeutics in October 2023. At Horizon, he was senior vice president and general manager of the gout and ophthalmology business units, where he led operations for franchises that represented $2.75 billion in net sales revenue.
Prior to his time at Horizon, from 2010 to 2021, Mr Foster held roles of increasing responsibility in sales and marketing at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as vice president of immunology marketing, senior global marketing director and field sales vice president.
Mr Foster began his career in sales and market access at Johnson & Johnson. Mr Foster holds a Bachelor of Arts in Economics from the University of Georgia and a Master of Business Administration from Auburn University.
